Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792335 | 0.79 | FSCN1 (0.41) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL850628 | 0.79 | ALDH1A1 (0.46) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL1781808 | 0.77 | FSCN1 (0.46) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL22324852 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL13476181 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL850191 | 0.75 | ALDH1A1 (0.50) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL792489 | 0.72 | ALDH1A1 (0.40) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL14341655 | 0.72 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL8430102 | 0.72 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL969001 | 0.71 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | SMN1; SMN2 1005/4885POLB 4431/4885ALDH1A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.